Education
About Us
Working with TipRanks
Follow Us
Arcus Biosciences Inc (RCUS)
NYSE:RCUS
RCUS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$6.50 - $18.98
Previous CloseN/A
Volume107.84K
Average Volume (3M)909.54K
Market Cap
$1.49B
Enterprise Value$64.91M
Total Cash (Recent Filing)$911.00M
Total Debt (Recent Filing)$109.00M
Price to Earnings (P/E)―
Beta2.07
Next Earnings
Nov 11, 2025EPS Estimate
-1.31Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.00
Shares Outstanding106,430,980
10 Day Avg. Volume1,029,959
30 Day Avg. Volume909,543
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.04
Enterprise Value/Revenue0.25
Enterprise Value/Gross Profit0.25
Enterprise Value/Ebitda-0.23
Forecast
1Y Price Target
$31.80Price Target Upside111.30% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
Bulls Say, Bears Say
Bulls Say
Drug EfficacyUpdated data on the Cas monotherapy for kidney cancer showed encouraging results, supporting its durable efficacy profile.
Financial PositionArcus Biosciences ended the quarter with significant cash and investments, expected to fund operations through key initial readouts, providing a strong financial position.
Pipeline PotentialThe introduction of a program for autoimmune and inflammatory diseases highlights the optionality and potential growth of the company's portfolio.
Bears Say
Clinical UncertaintyWhile recognizing the strength of its drug discovery capabilities, it's likely to take a while before investors attribute much value to the portfolio due to clinical uncertainties and the relatively higher costs of development.
Commercial ChallengesThere’s more investor uncertainties over whether the team can achieve its expansive commercial plans in RCC due to a fragmented market and lack of a commercial partner.
Arcus Biosciences News
RCUS FAQ
What was Arcus Biosciences Inc’s price range in the past 12 months?
Arcus Biosciences Inc lowest stock price was $6.50 and its highest was $18.98 in the past 12 months.
What is Arcus Biosciences Inc’s market cap?
Arcus Biosciences Inc’s market cap is $1.49B.
When is Arcus Biosciences Inc’s upcoming earnings report date?
Arcus Biosciences Inc’s upcoming earnings report date is Nov 11, 2025 which is in 33 days.
How were Arcus Biosciences Inc’s earnings last quarter?
Arcus Biosciences Inc released its earnings results on Aug 06, 2025. The company reported $0 earnings per share for the quarter, beating the consensus estimate of -$1.126 by $1.126.
Is Arcus Biosciences Inc overvalued?
According to Wall Street analysts Arcus Biosciences Inc’s price is currently Undervalued.
Does Arcus Biosciences Inc pay dividends?
Arcus Biosciences Inc does not currently pay dividends.
What is Arcus Biosciences Inc’s EPS estimate?
Arcus Biosciences Inc’s EPS estimate is -1.31.
How many shares outstanding does Arcus Biosciences Inc have?
Arcus Biosciences Inc has 106,430,980 shares outstanding.
What happened to Arcus Biosciences Inc’s price movement after its last earnings report?
Arcus Biosciences Inc reported an EPS of $0 in its last earnings report, beating expectations of -$1.126. Following the earnings report the stock price went down -2.213%.
Which hedge fund is a major shareholder of Arcus Biosciences Inc?
Currently, no hedge funds are holding shares in RCUS
Arcus Biosciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$31.80 (111.30% Upside)
$31.80 (111.30% Upside)
Blogger Sentiment
Bullish
RCUS Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 1.2M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 3.1%
Last 30 Days ▲ 7.5%
Last 30 Days ▲ 7.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-18.90%
12-Months-Change
Fundamentals
Return on Equity
-50.34%
Trailing 12-Months
Asset Growth
-9.36%
Trailing 12-Months
Company Description
Arcus Biosciences Inc
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for monotherapy. The company also develops Domvanalimab, an anti-TIGIT monoclonal antibody, which is in Phase 2 development for the treatment of first-line metastatic non-small cell lung cancer in combination with Zimberelimab; Quemliclustat, a small-molecule CD73 inhibitor is in a Phase 1/1b study for the treatment of first-line metastatic pancreatic cancer; and AB521, an oral and small molecule HIF-2a inhibitor that is in Phase 1 study for the treatment of patients with von Hippel- Lindau disease. It has a clinical development collaboration agreement with Strata Oncology, Inc. to evaluate Zimberelimab; a collaboration with AstraZeneca, BVF Partners L.P to evaluate domvanalimab, its investigational anti-TIGIT antibody, in combination with Imfinzi (durvalumab) in a registrational Phase 3 clinical trial in patients with unresectable Stage III non-small cell lung cancer; and license agreements with Taiho Pharmaceutical Co., Ltd, Abmuno Therapeutics LLC, and WuXi Biologics to develop anti-CD39 antibody for the treatment of cancer. The company was incorporated in 2015 and is headquartered in Hayward, California.
RCUS Stock 12 Month Forecast
Average Price Target
$31.80
▲(111.30% Upside)
Technical Analysis
Anavex Life Sciences
―
Spyre Therapeutics
―
Replimune Group
―
Sana Biotechnology
―
Verve Therapeutics
―
Ownership Overview
6.46% Insiders
15.23% Mutual Funds
51.34% Other Institutional Investors
11.54% Public Companies and
Individual Investors